Metreleptin treatment in patients with non-HIV associated lipodystrophy

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 9, Issue 2, 2015, Pages 74-78

  Akinci, Gulcin ^a   Akinci, Baris ^b  

^a Behcet Uz Children's Hospital   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Diabetes; Fat loss; Hepatic steatosis; Hypertriglyceridemia; Insulin resistance; Lipodystrophy; Metreleptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; METRELEPTIN; LEPTIN;

BROWN ADIPOSE TISSUE; CALORIC INTAKE; CONGENITAL GENERALIZED LIPODYSTROPHY; DRUG SAFETY; FAMILIAL PARTIAL LIPODYSTROPHY; FATIGUE; FATTY LIVER; HUMAN; HYPERGLYCEMIA; HYPERPHAGIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LEPTIN DEFICIENCY; LIFESTYLE MODIFICATION; LIPODYSTROPHY; NON HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED LIPODYSTROPHY; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANALOGS AND DERIVATIVES; ANIMAL; CLASSIFICATION; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; HUMANS; LEPTIN; LIPODYSTROPHY;

EID: 84953395615     PISSN: 18722148     EISSN: 22123334     Source Type: Journal    
DOI: 10.2174/1574892811666151111142554     Document Type: Review

References (73)

1. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006; 14 (Suppl 5): 242S-9S.
2. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: An endocrine organ. Arch Med Sci 2013; 9(2): 191-200.
3. Lowell BB, Spiegelman BM. Towards a molecular understanding of adaptive thermogenesis. Nature 2000; 404(6778): 652-60.
4. Ibrahim MM. Subcutaneous and visceral adipose tissue: Structural and functional differences. Obes Rev 2010; 11(1): 11-8.
5. Giralt M, Villarroya F. White, brown, beige/brite: Different adipose cells for different functions? Endocrinology 2013; 154(9): 2992-3000.
6. Poekes L, Lanthier N, Leclercq IA. Brown adipose tissue: A potential target in the fight against obesity and the metabolic syndrome. Clin Sci (Lond) 2015; 129(11): 933-49.
7. Cohen P, Spiegelman BM. Brown and beige fat: Molecular parts of a thermogenic machine. Diabetes 2015; 64(7): 2346-51.
8. Garg A. Lipodystrophies. Am J Med 2000; 108(2): 143-52.
9. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350(12): 1220-34.
10. Garg A. Clinical review#: Lipodystrophies: Genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011; 96(11): 3313-25.
11. Garg A, Misra A. Lipodystrophies: Rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 2004; 33(2): 305-31.
12. Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: Metabolic insights from a rare disorder. J Endocrinol 2010; 207(3): 245-55.
13. Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol 2008; 6(9): e237.
14. Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia 2002; 45(9): 1201-10.
15. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89(6): 2548-56.
16. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2010; 53(1): 27-35.
17. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007; 87(2): 507-20.
18. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: Unravelling the mechanism. Lancet 2010; 375(9733): 2267-77.
19. Agarwal AK, Arioglu E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002; 31(1): 21-23.
20. Magre J, Delepine M, Khallouf E, Gedde-Dahl T, Jr., Van Maldergem L, Sobel E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001; 28(4): 365-70.
21. Kim CA, Delepine M, Boutet E, El Mourabit H, Le Lay S, Meier M, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab 2008; 93(4): 1129-34.
22. Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, Mitsuhashi S, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest 2009; 119(9): 2623-33.
23. Shastry S, Delgado MR, Dirik E, Turkmen M, Agarwal AK, Garg A. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am J Med Genet A 2010; 152A(9): 2245-53.
24. Takeuchi K, Reue K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am J Physiol Endocrinol Metab 2009; 296(6): E1195-209.
25. Agarwal AK, Garg A. Genetic disorders of adipose tissue development, differentiation, and death. Annu Rev Genomics Hum Genet 2006; 7: 175-99.
26. Cohen AW, Razani B, Schubert W, Williams TM, Wang XB, Iyengar P, et al. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes 2004; 53(5): 1261-70.
27. Garg A, Agarwal AK. Caveolin-1: A new locus for human lipodystrophy. J Clin Endocrinol Metab 2008; 93(4): 1183-5.
28. Peters JM, Barnes R, Bennett L, Gitomer WM, Bowcock AM, Garg A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat Genet 1998; 18(3): 292-95.
29. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002; 87(1): 408-11.
30. Gandotra S, Le Dour C, Bottomley W, Cervera P, Giral P, Reznik Y, et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med 2011; 364(8): 740-8.
31. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 2004; 304(5675): 1325-8.
32. Farhan SM, Robinson JF, McIntyre AD, Marrosu MG, Ticca AF, Loddo S, et al. A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy. Can J Cardiol 2014; 30(12): 1649-54.
33. Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med 2009; 1(5): 280-7.
34. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl 1996; 413: 2-28.
35. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: Case reports and review of the literature. Medicine (Baltimore) 2003; 82(2): 129-46.
36. Eren E, Ozkan TB, Cakir ED, Saglam H, Tarim O. Acquired generalized lipodystrophy associated with autoimmune hepatitis and low serum C4 level. J Clin Res Pediatr Endocrinol 2010; 2(1): 39-42.
37. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenileonset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008; 87(2): 70-86.
38. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: Report of 35 cases and review of the literature. Medicine (Baltimore) 2004; 83(1): 18-34.
39. Akinci B, Koseoglu FD, Onay H, Yavuz S, Altay C, Simsir IY, et al. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metabolism 2015; 64(9): 1086-95.
40. Chou K, Perry CM. Metreleptin: First global approval. Drugs 2013; 73(9): 989-97.
41. Tchang BG, Shukla AP, Aronne LJ. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives. Expert Opin Biol Ther 2015; 15(7): 1061-75.
42. Polyzos SA, Mantzoros CS. Leptin in health and disease: Facts and expectations at its twentieth anniversary. Metabolism 2015; 64(1): 5-12.
43. Ahima RS, Osei SY. Leptin signaling. Physiol Behav 2004; 81(2): 223-41.
44. Ahima RS, Osei SY. Molecular regulation of eating behavior: New insights and prospects for therapeutic strategies. Trends Mol Med 2001; 7(5): 205-13.
45. Ahima R, Osei SY. Leptin and appetite control in lipodystrophy. J Clin Endocrinol Metab 2004; 89(9): 4254-7.
46. McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, De-Paoli AM, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 2004; 89(9): 4258-63.
47. Bluher M, Mantzoros CS. From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century. Metabolism 2015; 64(1): 131-45.
48. Minokoshi Y, Toda C, Okamoto S. Regulatory role of leptin in glucose and lipid metabolism in skeletal muscle. Indian J Endocrinol Metab 2012; 16(Suppl 3): S562-8.
49. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109(10): 1345-50.
50. Lehr S, Hartwig S, Sell H. Adipokines: A treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl 2010; 6(1-2): 91-101.
51. Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, et al. The liver diseases of lipodystrophy: The long-term effect of leptin treatment. J Hepatol 2013; 59(1): 131-7.
52. Frank S, Heni M, Moss A, von Schnurbein J, Farooqi S, Haring HU, et al. Long-term stabilization effects of leptin on brain functions in a leptin-deficient patient. PLoS One 2013; 8(6): e65893.
53. Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 2004; 53(4): 513-9.
54. Aotani D, Ebihara K, Sawamoto N, Kusakabe T, Aizawa-Abe M, Kataoka S, et al. Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy. J Clin Endocrinol Metab 2012; 97(10): 3663-71.
55. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346(8): 570-8.
56. Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: Baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 2004; 89(7): 3199-207.
57. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005; 54(7): 1994-2002.
58. Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract 2011; 17(6): 922-32.
59. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 2007; 92(2): 532-41.
60. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002; 87(5): 2395.
61. Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: Comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab 2015; 100(5): 1802-10.
62. Simha V, Subramanyam L, Szczepaniak L, Quittner C, Adams-Huet B, Snell P, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab 2012; 97(3): 785-92.
63. Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Longterm efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism 2007; 56(4): 508-16.
64. Brown RJ, Chan JL, Jaffe ES, Cochran E, DePaoli AM, Gautier JF, et al. Lymphoma in acquired generalized lipodystrophy. Leuk Lymphoma 2015; 12: 1-6.
65. Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: Facts and expectations. Metabolism 2015; 64(1): 146-56.
66. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004; 351(10): 987-97.
67. Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, et al. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci USA 2011; 108(16): 6585-90.
68. Sienkiewicz E, Magkos F, Aronis KN, Brinkoetter M, Chamberland JP, Chou S, et al. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism 2011; 60(9): 1211-21.
69. Byers, C., Caplan, S. L., Gamber, G. G., Hahm, S., Heldwein, K. A., Splawski, I., Zabawa, T., Zecri, F. Leptin mRNA compositions and formulations. WO2015095351 (2015).
70. Cheung, M., Tangirala, R. S. Novel compound as a diacylglycerol acyltransferase inhibitor. WO2015049667 (2015).
71. Matteuzzi, M. Filler composition for the treatment of lipoatrophy. WO2014162252 (2014).
72. Kiehm, K., Hauptmeier, B., Boderke, P. Filler comprising beads. US20150010603 (2015).
73. Koob, T. J., Brown, R. J. C. Cosmetic uses of molded placental compositions. US20150086634 (2015).